Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Francesco PorpigliaCristian FioriDaniele AmparoreGregor KadnerArya ManitMassimo ValerioNicolaas LumenBrian Sze Ho HoSergio AlonsoClaude SchulmanNeil BarberPublished in: BJU international (2018)
iTIND implantation is feasible, safe and effective in providing relief of BPH-related symptoms, at least until 12 months postoperatively. Sexual and ejaculatory functions are fully preserved. Further studies with a longer follow-up period are needed to assess the durability of these results and to clearly define the indications for iTIND implantation.